Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 10, 2008, Pages 1685-1686

  Ginsberg, Henry N ^a   Ramakrishnan, Rajasekhar ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; ATORVASTATIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE; TRIACYLGLYCEROL;

DRUG EFFECT; EDITORIAL; ENZYME ACTIVITY; HUMAN; LIPID METABOLISM; LIPOLYSIS; PRIORITY JOURNAL; PROTEIN METABOLISM; BLOOD; DOWN REGULATION; DYSLIPIDEMIA; KINETICS; MALE; METABOLIC SYNDROME X; METHODOLOGY; NOTE; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; APOLIPOPROTEIN C-III; APOLIPOPROTEINS; APOLIPOPROTEINS A; APOLIPOPROTEINS B; CHOLESTEROL; DOWN-REGULATION; DYSLIPIDEMIAS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KINETICS; LIPOPROTEINS, VLDL; MALE; METABOLIC SYNDROME X; PROCETOFEN; PYRROLES; RESEARCH DESIGN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 53449099510     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.174185     Document Type: Editorial

References (9)

1. Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1831-1837.
2. Eisenberg S, Patsch JR, Sparrow JT, Gotto AM, Olivecrona T. Very low density lipoprotein. Removal of Apolipoproteins C-II and C-III-1 during lipolysis in vitro. J Biol Chem. 1979;254:12603-12608.
3. Huff M, Fidge NH, Nestel PJ, Billington T, Watson B. Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects. J Lipid Res. 1981;22:1235-1246.
4. Berman M, Hall M 3rd, Levy RI, Eisenberg S, Bilheimer DW, Phair RD, Goebel RH. Metabolsim of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteininemic subjects. J Lipid Res. 1978;19:38-56.
5. Bukberg PR, Le NA, Ginsberg HN, Gibson JC, Rubinstein A, Brown WV. Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins. J Lipid Res. 1985;26:1047-1057.
6. Cohn JS, Tremblay M, Batal R, Jacques H, Rodriguez C, Steiner G, Mamer O, Davignon J. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis. 2004;177:137-145.
7. Chan DC, Nguyen MN, Watts GF, Barrett PH. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. J Clin Endocrin Metab. 2008;93:557-564.
8. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN. J Clin Invest. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. 2005;115:1323-1332.
9. Pavlic M, Valero R, Duez H, Xiao C, Szeto L, Patterson BW, Lewis GF. Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol. 2008;28:1660-1665.